ARAlex J. Rai

Alex J. Rai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alex J. Rai has a total of 128 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Contributors

    by Thomas M. Annesley, Fred S. Apple, Edward R. Ashwood, Michael N. Badminton, Renze Bais, James C. Barton, Howard J. Baum, Lindsay A.L. Bazydlo, Laura Bechtel, Roger L. Bertholf, et al.

  • Analysis of Human Proteome Organization Plasma Proteome Project (HUPO PPP) reference specimens using surface enhanced laser desorption/ionization‐time of flight (SELDI‐TOF) mass spectrometry: Multi‐institution correlation of spectra and identification of biomarkers

    by Alex J. Rai, Paul M. Stemmer, Zhen Zhang, Bao‐Ling Adam, William T. Morgan, Rebecca E. Caffrey, Vladimir N. Podust, Manisha Patel, Lih‐Yin Lim, Natalia V. Shipulina, et al.

    We report on a multicenter analysis of HUPO reference specimens using SELDI‐TOF MS. Eight sites submitted data obtained from serum and plasma reference specimen analysis. Spectra from five sites passed preliminary quality assurance tests and were subjected to further analysis. Intralaboratory CVs varied from 15 to 43%. A correlation coefficient matrix generated using data from these five sites demonstrated high level of correlation, with values >0.7 on 37 of 42 spectra. More than 50 peaks were differentially present among the various sample types, as observed on three chip surfaces. Additionally, peaks at ∼9200 and ∼15 950 m/z were present only in select reference specimens. Chromatographic fractionation using anion‐exchange, membrane cutoff, and reverse phase chromatography, was employed for protein purification of the ∼9200 m/z peak. It was identified as the haptoglobin alpha subunit after peptide mass fingerprinting and high‐resolution MS/MS analysis. The differential expression of this protein was confirmed by Western blot analysis. These pilot studies demonstrate the potential of the SELDI platform for reproducible and consistent analysis of serum/plasma across multiple sites and also for targeted biomarker discovery and protein identification. This approach could be exploited for population‐based studies in all phases of the HUPO PPP.


  • Top Cited Papers

    HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples

    by Alex J. Rai, Craig A. Gelfand, Bruce C. Haywood, David J. Warunek, Jizu Yi, Mark D. Schuchard, Richard J. Mehigh, Steven L. Cockrill, Graham B. I. Scott, Harald Tammen, et al.

    There is a substantial list of pre‐analytical variables that can alter the analysis of blood‐derived samples. We have undertaken studies on some of these issues including choice of sample type, stability during storage, use of protease inhibitors, and clinical standardization. As there is a wide range of sample variables and a broad spectrum of analytical techniques in the HUPO PPP effort, it is not possible to define a single list of pre‐analytical standards for samples or their processing. We present here a compendium of observations, drawing on actual results and sound clinical theories and practices. Based on our data, we find that (1) platelet‐depleted plasma is preferable to serum for certain peptidomic studies; (2) samples should be aliquoted and stored preferably in liquid nitrogen; (3) the addition of protease inhibitors is recommended, but should be incorporated early and used judiciously, as some form non specific protein adducts and others interfere with peptide studies. Further, (4) the diligent tracking of pre‐analytical variables and (5) the use of reference materials for quality control and quality assurance, are recommended. These findings help provide guidance on sample handling issues, with the overall suggestion being to be conscious of all possible pre‐analytical variables as a prerequisite of any proteomic study.


  • Cancer Proteomics: Serum Diagnostics for Tumor Marker Discovery

    by Alex J. Rai, Daniel W. Chan

    Abstract: Cancer proteomics is an exciting field that is witnessing many new developments in recent years. It is hoped that these advances will result in decreased cancer death rates, which have not declined dramatically in the last several decades. Some of the problems with current tumor markers include the lack of sensitivity and specificity, factors that prevent their use in population‐based screening of disease. Thus, there is an urgent need to identify novel biomarkers that can faithfully detect the disease state. As we are now in the post‐genome era, many opportunities have been created. Genomic sequence data are available for human, as well as several other species. We are now poised to mine these data and to determine the functions of the encoded proteins constituting the human genome. Proteomics affords this opportunity by providing enhanced procedures and tools for discovery and also a framework for understanding these components in terms of pathogenesis. New technologies and improvements in existing methodologies will allow for the rapid growth in the identification and characterization of peptides and proteins that are unique to various clinical states. This technology can be successfully applied to clinical specimens for the identification of new tumor markers.


  • Proteomic approaches to tumor marker discovery.

    by Alex J Rai, Zhen Zhang, Jason Rosenzweig, Ie-Ming Shih, Thang Pham, Eric T Fung, Lori J Sokoll, Daniel W Chan

    Current tumor markers for ovarian cancer still lack adequate sensitivity and specificity to be applicable in large populations. High-throughput proteomic profiling and bioinformatics tools allow for the rapid screening of a large number of potential biomarkers in serum, plasma, or other body fluids. To determine whether protein profiles of plasma can be used to identify potential biomarkers that improve the detection of ovarian cancer. We analyzed plasma samples that had been collected between 1998 and 2001 from patients with sporadic ovarian serous neoplasms before tumor resection at various International Federation of Gynecology and Obstetrics stages (stage I [n = 11], stage II [n = 3], and stage III [n = 29]) and from women without known neoplastic disease (n = 38) using proteomic profiling and bioinformatics. We compared results between the patients with and without cancer and evaluated their discriminatory performance against that of the cancer antigen 125 (CA125) tumor marker. We selected 7 biomarkers based on their collective contribution to the separation of the 2 patient groups. Among them, we further purified and subsequently identified 3 biomarkers. Individually, the biomarkers did not perform better than CA125. However, a combination of 4 of the biomarkers significantly improved performance (P < or =.001). The new biomarkers were complementary to CA125. At a fixed specificity of 94%, an index combining 2 of the biomarkers and CA125 achieves a sensitivity of 94% (95% confidence interval, 85%-100.0%) in contrast to a sensitivity of 81% (95% confidence interval, 68%-95%) for CA125 alone. The combined use of bioinformatics tools and proteomic profiling provides an effective approach to screen for potential tumor markers. Comparison of plasma profiles from patients with and without known ovarian cancer uncovered a panel of potential biomarkers for detection of ovarian cancer with discriminatory power complementary to that of CA125. Additional studies are required to further validate these biomarkers.